

# Development and Validation of HPLC Method for Simultaneous Estimation of Brimonidine Tartrate and Timolol Maleate in Bulk and Pharmaceutical Dosage Form

Abdullah A Elshanawane<sup>1</sup>, Lobna M Abdelaziz<sup>1</sup>, Mustafa S Mohram<sup>2</sup> and Hany M Hafez<sup>2\*</sup>

<sup>1</sup>Medicinal Chemistry Department, Zagazig University, Zagazig, Egypt

<sup>2</sup>Quality control department, EIPICO, Egypt

## Abstract

Brimonidine tartrate and Timolol Maleate are used in treatment of glaucoma by decreasing intra ocular pressure. A validated HPLC method was developed for the assay of them. The method was performed on BDS HYPERSIL Cyano column (250×4.6 mm, 5 μ) and the mobile phase consisted of Ammonium acetate (pH 5.0, 0.01 M) - Methanol (40:60, V/V) which pumped at a flow rate equals to 1.5 ml/min at ambient temperature. 20 μl of drugs sample solutions were monitored at two fixed wavelengths (λ=254.0 nm for Brimonidine Tartrate and 300.0 nm for Timolol Maleate). The proposed method was validated in terms of linearity, accuracy, precision and limits of detection and quantitation according to ICH.

**Keywords:** Brimonidine Tartrate; Timolol Maleate

**Abbreviations:** HPLC: High Performance Liquid Chromatography

## Introduction

Glaucoma describes a group of disorders characterized by a loss of visual field associated with cupping of the optic disc and optic nerve damage. Glaucoma is generally associated with raised intra-ocular pressure. Forms of glaucoma are primary open-angle glaucoma and primary angle closure glaucoma. Drugs that reduce intra-ocular pressure by different mechanisms are available for managing glaucoma. A topical beta-blocker or a prostaglandin analogue is usually the drug of first choice. It may be necessary to combine these drugs or add others, such as miotics, carbonic anhydrase inhibitors or *sympathomimetics* to control intra-ocular pressure [1].

Timolol Maleate is (2S)-1-[(1, 1- dimethyl ethyl amino)-3-[[4-(morpholin-4- yl)-1, 2, 5-thiadiazol-3-yl] oxy] propan-2-ol (Z)-butenedioate (Figure 1), it is a non-cardioselective beta blocker. It is reported to lack intrinsic sympathomimetic and membrane-stabilising activity. Timolol Maleate is used in the management of glaucoma, hypertension, angina pectoris and myocardial infarction [1]. Brimonidine is 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine (Figure 1), it is a selective alpha -adrenoceptor agonist, is licensed for the reduction of intra-ocular pressure in open-angle glaucoma or ocular hypertension in patients for whom beta-blockers are inappropriate; it may also be used as adjunctive therapy when intra-ocular pressure is inadequately controlled by other anti-glaucoma therapy [1]. Eye drops (Combigan eye drop) containing Timolol Maleate equivalent to 0.5% of timolol and 0.2% of Brimonidine are instilled twice daily to reduce raised intra-ocular pressure in open-angle glaucoma and ocular hypertension.

Literature review reveals that different methods have been reported for estimation of both drugs individually like, RP-HPLC for the Analysis of Brimonidine in Ophthalmic Formulations [2,3], in blood serum and aqueous humor of the eye [4] and LC/MS/MS HPLC for the Analysis of Brimonidine in Ocular Fluids and Tissues [5]. Three papers discussed stability of Brimonidine tartrate [6-8], other analytical techniques were reported for determination of Brimonidine tartrate like HPTLC [9], GC/MS [10] and CE [11].

Timolol Maleate is listed in USP which described RP-HPLC for determination Timolol maleate in eye drops [12]. BP estimated Timolol Maleate potentiometrically [13].


**\*Corresponding author:** Hany M. Hafez, Bachelor degree of Pharmaceutical Science, Zagazig University, Zagazig, Egypt Quality control department, EIPICO, 10th Ramadan, Egypt, Tel: 020113231458; E-mail: [hanyhaf\\_1982@yahoo.com](mailto:hanyhaf_1982@yahoo.com)

Received April 29, 2014; Accepted June 30, 2014; Published July 17, 2014


**Citation:** Elshanawane AA, Abdelaziz LM, Mohram MS, Hafez HM (2014) Development and Validation of HPLC Method for Simultaneous Estimation of Brimonidine Tartrate and Timolol Maleate in Bulk and Pharmaceutical Dosage Form. J Chromatograph Separat Techniq 5: 230. doi:[10.4172/2157-7064.1000230](https://doi.org/10.4172/2157-7064.1000230)

**Copyright:** © 2014 Elshanawane AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Brimonidine tartrate:



Timolol maleate:



**Figure 1:** Structures of Brimonidine Tartrate and Timolol Maleate respectively.



Literature review reveals several methods have been reported for the estimation of Timolol Maleate in biological fluids [14-19] and there are some methods reported by voltammetry [20], spectroscopy [21-23], HPTLC [24] HPLC [25-28], UPLC [29,30] and capillary electrophoresis [31]. Two methods were only reported for estimation of this combination, the first is HPTLC [32] and the other is HPLC method [33]. The latter does not fulfill all requirements of validation which will be discussed later. Development of HPLC method for simultaneous estimation of this combination is a must and our scope that our new method will fulfill all requirements of validation according to ICH guidelines. It should be characterized by simplicity, fast analysis, sensitivity and suitability for routine pharmaceutical analysis.

## Materials and Methods

### Instrumentation

Analysis was performed on a chromatographic system of WATERS 2695 separation module connected to WATERS 2487 UV/VIS detector. The system equipped by Empower PC program. The chromatographic separation was achieved on BDS HYPERSIL Cyano column (250×4.6 mm, 5 µ).

### Chemicals and reagents

All reagents used were of analytical grade or HPLC grade. Ammonium acetate and glacial acetic acid were supplied by (Merck, Darmstadt, Germany), Methanol HPLC grade was supplied by (Fischer scientific, U.K.) and Distilled water.

(Note: The water used in all the experiments was obtained from Milli-RO and Milli-Q systems (Millipore, Bedford, MA.)

Timolol Maleate and Brimonidine Tartrate working standard powders were kindly supplied by Egyptian international pharmaceutical industries company (EIPICO) (10<sup>th</sup> Ramadan, Egypt), and were used without further purification.

### Pharmaceutical preparation

Combigan eye drops, Allergan (U.S.A) contains (Brimonidine Tartrate 0.2% and Timolol (as Maleate) 0.5%) B.NO: E64005.

### Chromatographic condition

20 µl of drugs sample solutions were monitored at two fixed wavelengths ( $\lambda=254.0$  nm for Brimonidine Tartrate and 300.0 nm for Timolol Maleate). Liquid chromatography was performed on BDS HYPERSIL Cyano column (250×4.6 mm, 5 µ) and the mobile phase consisted of Ammonium acetate (pH 5.0, 0.01M) - Methanol (40:60, V/V) which pumped at a flow rate equals to 1.5 ml/min at ambient temperature.

Ammonium acetate (0.01 M) was prepared by dissolving 0.77 g Ammonium acetate in approximately 950 ml distilled water. The pH was adjusted to 5.0 with glacial acetic acid. Water was added to 1000 ml. Mobile phase was filtered through a 0.45 µl Nylon membrane filter (Millipore, Milford, MA, USA) under vacuum and degassed by ultrasonication (Cole Palmer, Vernon Hills, USA) before usage.

### Preparation of stock standard solutions

Stock standard solutions containing 0.2, 0.68 mg/ml of Brimonidine Tartrate and Timolol Maleate (equivalent to 0.5 mg/ml of Timolol) respectively were prepared by dissolving 20, 68 mg of each in distilled water in 100 ml volumetric flask respectively. It was then sonicated for 5 minutes and the final volume of solutions was made up to 100 ml with distilled water to get stock standard solutions.

### Preparation of calibration plot (working standard solutions)

To construct calibration plots, the stock standard solutions were diluted with distilled water to prepare working solutions in the concentration ranges (4-24 and 10-60 µg/ml) for of Brimonidine Tartrate and Timolol respectively. Each solution (n=5) was injected in triplicate and chromatographed under the mentioned conditions above. Linear relationships were obtained when average drug standard peak area were plotted against the corresponding concentrations for each drug. Regression equation was computed.

### Sample preparation

Take 1 ml of Combigan E/D into 100 ml V.F. then complete with distilled water. Test solutions were analyzed under optimized chromatographic conditions and chromatogram is depicted in (Figure 2).


### Method validation

**Specificity:** Specificity is the ability to assess unequivocally the analyte in the presence of components which may be expected to be present. Typically these might include impurities, degradants, matrix, etc [34]. A Bulk of Combigan E/D (solution contains excipients only) was prepared by mixing its excipients like benzalkonium chloride 0.005%; sodium phosphate, monobasic; sodium phosphate, dibasic and purified water then the bulk was injected under previous condition. Representative chromatogram showed that the bulk has negligible contribution after the void volume at the method detection wavelengths i.e. it did not interfere with developed method.

**Linearity and range:** The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sample. For the establishment of linearity, a minimum of 5 concentrations is recommended [34]. Five Concentrations were chosen in the ranges (4-24 and 10-60 µg/ml) for corresponding levels of 20-120% w/w of the nominal analytical concentration of Brimonidine Tartrate and Timolol respectively. The linearity of peak area responses versus concentrations was demonstrated by linear least square regression analysis. The linear regression equations were  $\{Y=42167 X - 4937 (r=0.9999)$  and  $Y=22395 X - 8914 (r=0.9998)\}$  for Brimonidine Tartrate and Timolol Maleate respectively. Where Y is the peak area of standard solution and X is the drug concentration (Figure3).

**Precision:** The precision of the assay was investigated by measurement of both repeatability and Intermediate precision.

**Repeatability:** Repeatability was investigated by injecting a minimum of 6 determinations at 100% of the test concentration and percentage SD were calculated in Table 1.



**Figure 3:** Calibration plot of Brimonidine Tartrate and Timolol Maleate.

Drug name	Brimonidine Tartrate		Timolol Maleate		
	AV ± SD mg/ml	AV ± SD %	AV ± SD mg/ml	AV ± SD %	
Repeatability	19.98 ± 0.19	99.88 ± 0.94%	49.90 ± 0.50	99.81 ± 1.00%	
Intermediate precision	19.99 ± 0.32	99.9 ± 1.59%	49.78 ± 0.84	99.56 ± 1.67%	
Accuracy & Recovery %	80%	15.99 ± 0.13	99.94 ± 0.78%	40.21 ± 0.43	100.53 ± 1.06%
	100%	20.06 ± 0.15	100.32 ± 0.75%	50.01 ± 0.51	100.01 ± 1.02%
	120%	24.20 ± 0.19	100.83 ± 0.80%	60.34 ± 0.43	100.57 ± 0.72%

**Table 1:** Repeatability and Intermediate precision and Accuracy (Recovery %) of Brimonidine Tartrate and Timolol Maleate respectively.

**Intermediate precision:** In the inter-day studies, standard and sample solutions prepared as described above, were analyzed in triplicate on three consecutive days at 100% of the test concentration and percentage SD were calculated (Table 1).

**Accuracy:** Accuracy was assessed using 9 determinations over 3 concentration levels covering the specified range (80,100 and 120%). Accuracy was reported as percent recovery by the assay of known added amount of analytes in the sample (Table 1).

**Limits of detection and Limits of quantitation:** According to the ICH recommendations, determination of limits of detection and quantitation was based on the standard deviation of the y-intercepts of regression lines (n=3) and the slope of the calibration plots [34] (Table 2).

**Robustness:** Robustness of an analytical procedure is a measure of its capacity to remain unaffected by small variations in method parameters and provides an indication of its reliability during normal usage [34]. Robustness was tested by studying the effect of changing mobile phase pH by ± 0.5, the percentage of organic solvent (methanol) in the mobile phase by ± 5 %, temperature ± 5°C, wavelengths ± 5 nm and flow rate ± 0.1 ml/min had no significant effect on the chromatographic resolution of the method.

**Stability of analytical solution:** Also as part of evaluation of robustness, solution stability was evaluated by monitoring the peak

area response. Standard stock solutions in methanol were analyzed right after its preparation 1, 2 and 3 days after at room temperature. The change in standard solution peak area response over 3 days was (1.01 and 0.89 %) for Brimonidine Tartrate and Timolol Maleate respectively. Their solutions were found to be stable for 3 days at room temperature at least.

### Application on Pharmaceutical Preparation

The proposed methods were successfully used to determine Brimonidine Tartrate and Timolol Maleate respectively in Combigan E/D. Five replicate determinations were performed. Satisfactory results were obtained for each compound in good agreement with label claims. The results obtained were compared statistically with those from published method [33] by using Student's t-test and the variance ratio F-test. The results showed that the t and F values were smaller than the critical values. So, there were no significant differences between the results obtained from this method and published methods (Table 3).

### Results and Discussion

#### Optimization of chromatographic condition

Several trials were carried out to obtain optimized chromatographic condition for simultaneous determination of Brimonidine Tartrate and Timolol Maleate in their pharmaceutical preparations. Firstly, maximum absorption wavelengths (254,300 nm) for Brimonidine Tartrate and

Item	Brimonidine Tartrate	Timolol Maleate
Linear range (µg/ml)	4-24	10-60
Detection limit (µg/ml)	0.05	0.09
Quantitation limit (µg/ml)	0.15	0.29
Regression data		
No.	5	5
slope (b)	42167	22395
Standard deviation of the slope	56.36	36.67
intercept (a)	4937	8914
Standard deviation of the intercept	637.86	641.36
correlation coefficient @	0.9999	0.9998
Standard error of regression	0.09	0.3


( $Y = a + bC$ , where C is the concentration of the compound (µg/ml) and Y is the drug peak area)

**Table 2:** Calibration data was resulted from method validation of Brimonidine Tartrate and Timolol Maleate respectively.

Drug name	Recovery ± SD		Calculated t- values	Calculated F- values
	Proposed methods	Reference method		
Brimonidine Tartrate	101.41 ± 0.95	100.85 ± 1.00	2.49	0.94
Timolol Maleate	101.40 ± 1.32	101.23 ± 1.16	1.13	1.28

(Where the Tabulated t-values and F -ratios at p= 0.05 are 2.57 and 5.05)

**Table 3:** Statistical comparison of the proposed and published methods for determination of Brimonidine Tartrate and Timolol Maleate respectively in their dosage forms by reported method (T- student test) and (F –test for variance).



**Figure 4:** Typical UV spectrum of Brimonidine Tartrate and Timolol Maleate.

Timolol Maleate were selected by scanning from 350-200 nm under UV (Figure 4). Ammonium acetate buffer has no effect on absorption at wavelength more than 250 nm [35]. Low conc. of buffer (0.01M) is adequate for most reversed phase applications. This concentration is also low enough to avoid problems with precipitation when significant amounts of organic modifiers are used in the mobile phase [36]. PH of acetate buffer was examined, at pH=3 interference between maleic acid peak and solvent peak had occurred but interference disappeared at pH=5. Different percentages of organic solvent (methanol) were tried with acetate buffer to reach optimum separation with good resolution. 60% methanol in mobile phase gave adequate separation and resolution. Using Cyano column enabled us to produce sharp and symmetric peaks because it is better in separation of drug containing basic functionality like amino compounds [37].

## References

- BMJ Group (2011) British national formulary 62. (1stedn), Pharmaceutical Press, London.
- Narendra A, Deepika D, Annapurna MM (2012) Liquid chromatographic method for the analysis of brimonidine in ophthalmic formulations. *E-J Chem* 9: 1327-1331.
- Shirke RR, Pai N (2002) RP-HPLC determination of brimonidinetartrate in brimonidine tartrate eye drops. *Ind Drugs* 39: 484-486.
- Karamanos NK, Lamari F, Katsimpris J, Gartaganis S (1999) Development of an HPLC method for determining the alpha2-adrenergic receptor agonist brimonidine in blood serum and aqueous humor of the eye. *Biomed Chromatogr* 13: 86-88.
- Jiang S, Chappa SK, Proksch JW (2009) A Rapid and Sensitive LC/MS/MS Assay for the Quantitation of Brimonidine in Ocular Fluids and Tissues. *J Chromatogr B Analyt Technol Biomed Life Sci* 877: 107-114.
- Ali MS, Khatri AR, Munir MI, Ghori M (2007) A Stability-Indicating Assay of Brimonidine Tartrate Ophthalmic Solution and Stress Testing Using HILIC. *Chromatographia* 70: 539-544.
- Bhagav P, Deshpande P, Pandey S, Chandran S (2010) Development and Validation of Stability Indicating UV Spectrophotometric Method for the Estimation of Brimonidine Tartrate in Pure Form, Formulations and Preformulation Studies. *Der Pharm Let* 2: 106-122.
- Sonanis MC, Rajput AP (2011) Development and validation of a new stability indicating analytical method for the determination of related components of brimonidine tartrate in drug substances and drug product using UPLC. *Int. J. Pharm Pharm Sci* 3: 156-160.
- Anand M, Fonseca A, Santosh GV, Padmanabh DB (2010) Development and Validation of High Performance Thin Layer Chromatographic Method for Estimation of Brimonidine Tartrate as Bulk Drug and in Ophthalmic Solutions. *Int. J. ChemTech Res* 2: 1376-1379.
- Acheampong A, Tang L, Diane DS (1995) Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay. *J Pharm Biomed Anal* 13: 995- 1002.
- Tzovolou DN, Lamari F, Mela EK, Gartaganis SP, Karamanos NK (2000) Capillary electrophoretic analysis of brimonidine in aqueous humor of the eye and blood sera and relation of its levels with intraocular pressure. *Biomed Chromatogr* 14: 301-305.
- <http://www.healthwise.org>
- <http://www.pharmacopoeia.co.uk>
- Nasir F, Iqbal Z, Khan A, Ahmad L, Shah Y, et al. (2011) Simultaneous determination of timolol maleate, rosuvastatin calcium and diclofenac sodium in pharmaceuticals and physiological fluids using HPLC-UV. *J Chromatogr B Analyt Technol Biomed Life Sci* 879: 3434-3443.
- Maguregui MI, Jimenez RM, Alonso RM, Akesolo U (2002) Quantitative determination of oxprenolol and timolol in urine by capillary zone electrophoresis. *J Chromatogr A* 949: 91-97.
- Olah TV, Gilbert JD, Barrish A (1993) Determination of the β-adrenergic blocker Timolol in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. *J Pharm Biomed Anal* 11: 157-163.
- Magureguia MI, Alonso RM, Jiménez RM (1996) A Rapid Quantitative Analysis of the β-Blocker Timolol in Human Urine by HPLC-Electrochemical Detection. *J Liq Chromatogr Rel Tech* 19: 1643-1652.
- He H, Edeki TI, Wood AJJ (1994) Determination of low plasma Timolol concentrations following topical application of timolol eye drops in humans by HPLC with electrochemical detection. *J Chromatogr B Biomed Appl.* 661: 351-356.
- Gilbert JD, Olah TV, Morris MJ, Bortnick A, Brunner J (1998) The Use of Stable Isotope Labeling and LC/ MS To Simultaneously Determine the Oral and Ophthalmic Bioavailability of Timolol in Dogs. *J Chromatogr Sci* 36: 163-168.
- Turkdemir MH, Erdogdu G, Aydemir T, Karagozler AA, Karagozler AE (2001) Voltammetric Determination of Timolol Maleate: A β-Adrenergic Blocking Agent. *J Anal. Chem* 56:1047-1050.
- Erk N (2002) Simultaneous determination of dorzolamide HCL and Timolol maleate in eye drops by two different spectroscopic methods. *J Pharm Biomed Anal* 28: 391-397.

22. Ferraro MC (2004) Chemometric determination of amiloride hydrochloride, atenolol, hydrochlorothiazide and timolol maleate in synthetic mixtures and pharmaceutical formulations. J Pharm Biomed Anal 34:305-314.
23. Ayad MM, Shalaby A, Abdellatif HE, Hosny MM (2003) Spectrophotometric methods for determination of enalapril and timolol in bulk and in drug formulations. Anal Bioanal Chem 375: 556-560.
24. Kulkarni SP, Amin PD (2000) Stability indicating HPTLC determination of timolol maleate as bulk drug and in pharmaceutical preparations. J Pharm Biomed Anal 23: 983-987.
25. Erk N (2003) Rapid and sensitive HPLC method for the simultaneous determination of dorzolamide hydrochloride and timolol maleate in eye drops with diode-array and UV detection. Pharmazie 58: 491-493.
26. Nagori BP, Maru A, Muysuni P, Gupta S (2011) Method Development and Its Validation for Simultaneous Estimation of Timolol Maleate and Dorzolamide Hydrochloride as API and In Ophthalmic Solution Dosage Form by RP-HPLC. J Chem Pharm Res 3: 866-874.
27. Wanare RS, Kabra AO, Deshmukh A, Aher N (2012) Simultaneous Estimation of Dorzolamide Hydrochloride And Timolol Maleate In Eye Drops By a RP-HPLC Method. Int J Compreh Pharm 3: 1-4.
28. Rele RV, Mhatre VV, Parab JM, Warkar CB (2011) Simultaneous RP HPLC determination of Latanoprost and Timolol Maleate in combined pharmaceutical dosage form. J Chem Pharm Res 3:138-144.
29. Sharma N, Rao SS, Reddy AM (2012) A Novel and Rapid Validated Stability-Indicating UPLC Method of Related Substances for Dorzolamide Hydrochloride and Timolol Maleate in Ophthalmic Dosage Form. J Chromatogr Sci. 50:745-755.
30. Mehta J, Patel V, Kshatri N, Vyas N (2010) A versatile LC method for the simultaneous quantification of latanoprost, timolol and benzalkonium chloride and related substances in the presence of their degradation products in ophthalmic solution. Anal. Methods 2:1737-1744.
31. Marini RD et al. (2006) Interlaboratory study of a NACE method for the determination of R-timolol content in S-timolol maleate: assessment of uncertainty. Electrophoresis 27:2386-2399.
32. Jain PS, Khatal RN, Jivani HN, Surana SJ (2011) Development and Validation of TLC-densitometry Method for Simultaneous Estimation of Brimonidine tartrate and Timolol maleate in Bulk and Pharmaceutical Dosage Form. J Chromatograph Separat Techniq 2:113-117.
33. Phogat A, Kumar MS, Mahadevan N (2011) Simultaneous Estimation of Brimonidine Tartrate and Timolol Maleate in Nanoparticles Formulation by RP-HPLC. Int J Rec Adv Pharm Res 3: 31-36.
34. ICH Guidelines (1996) Validation of Analytical Procedures: Text and Methodology. ICH.
35. Sethi PD (2001) High Performance liquid Chromatography quantitative analysis of pharmaceutical formulations. (1stedn), India
36. <http://www.mac-mod.com/pdf/TR-BufferedMP.pdf>
37. Adamovics JA et al. (1996) chromatographic analysis of pharmaceuticals. (2ndedn),USA

**Citation:** Eishanawane AA, Abdelaziz LM, Mohram MS, Hafez HM (2014) Development and Validation of HPLC Method for Simultaneous Estimation of Brimonidine Tartrate and Timolol Maleate in Bulk and Pharmaceutical Dosage Form. J Chromatograph Separat Techniq 5: 230. doi:[10.4172/2157-7064.1000230](https://doi.org/10.4172/2157-7064.1000230)

### Submit your next manuscript and get advantages of OMICS Group submissions

#### Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

#### Special features:

- 350 Open Access Journals
- 30,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.editorialmanager.com/biochem>